Sign up to our newsletter Subscribe
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Sign up to our newsletter Subscribe
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
An error has occurred, please try again later.